Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,treasuryStock,cash,totalCurrentLiabilities,otherStockholderEquity,totalCurrentAssets,longTermInvestments,netReceivables,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,changeToNetincome,investments,otherCashflowsFromInvestingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,HUGE,55532320.0,35991800,1970251,,-9405612,,-9939454,3048859,0,-9802654,-9802654,,-19325,,,,0,0,9802654,0,397042,-533842,-9405612,-9939454,12973371.0,19048240.0,7938675.0,68505691.0,2706350.0,76444366.0,145126408.0,8717943.0,-100808342.0,5139385.0,49838731.0,7868162.0,5139385.0,60832869.0,2638126.0,237076.0,2554222.0,1819679.0,-500000.0,-42936.0,38298471.0,-1416697.0,38341407.0,32313909.0,-5484562.0,951020.0,-52894.0,3153784.0,,,52964707.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,FSD Pharma Inc.,False,False,NCM,1.79,1630526403,-0.04000008,1.84,1.85,1.77,145980,PRE,0,4,-2.1857967,1.77 - 1.85,1.83,0.0,0.0,14,9,finmb_266208867,FSD Pharma Inc.,NasdaqCM,USD,346667,593357,0.51,0.3984375,1.28 - 4.44,-2.65,-0.5968469,1.28,4.44,1571184000,1615984200,1628166600,1628512200,1.6471429,0.14285707,0.08673023,1.8123913,-0.02239132,-0.012354572,64425320,15,America/New_York,EDT,-14400000,1.09,,,4.44,1.28,1.6471,1.8124,346.67k,593.36k,35.99M,,33.97M,12.91%,2.53%,945.83k,1.77,,2.63%,1.12M,,,,,,0.00%,"Oct 15, 2019",,1:201,"Oct 15, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-37.04%,-60.26%,,,,,-29.18M,-29.7M,,,49.84M,1.38,476.74k,0.70,7.73,,-19.12M,-2.78M,Value,M5X 1A4,Healthcare,9,"FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.",Toronto,416 854 8884,ON,1609372800,Canada,http://www.fsdpharma.com,86400,First Canadian Place,Drug Manufacturers—Specialty & Generic,Suite 3400 100 King Street West
t-1,HUGE,22884192.0,35991800,2223683,,-2906047,,-3193420,1989138,0,-4930706,-4930706,,-24212,,,,0,0,4930706,0,2024659,-287373,-2906047,-3193420,13424391.0,18792590.0,5658622.0,36308583.0,1447910.0,41967205.0,103208126.0,8610504.0,-90868888.0,5176755.0,17524822.0,5579502.0,5176755.0,26866069.0,1676745.0,161342.0,3700103.0,1330852.0,-281468.0,-336369.0,7569345.0,-4156297.0,7905714.0,3137631.0,-4150246.0,841247.0,3454533.0,-2427161.0,-279885.0,-1583.0,21286567.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,FSD Pharma Inc.,False,False,NCM,1.79,1630526403,-0.04000008,1.84,1.85,1.77,145980,PRE,0,4,-2.1857967,1.77 - 1.85,1.83,0.0,0.0,14,9,finmb_266208867,FSD Pharma Inc.,NasdaqCM,USD,346667,593357,0.51,0.3984375,1.28 - 4.44,-2.65,-0.5968469,1.28,4.44,1571184000,1615984200,1628166600,1628512200,1.6471429,0.14285707,0.08673023,1.8123913,-0.02239132,-0.012354572,64425320,15,America/New_York,EDT,-14400000,1.09,,,4.44,1.28,1.6471,1.8124,346.67k,593.36k,35.99M,,33.97M,12.91%,2.53%,945.83k,1.77,,2.63%,1.12M,,,,,,0.00%,"Oct 15, 2019",,1:201,"Oct 15, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-37.04%,-60.26%,,,,,-29.18M,-29.7M,,,49.84M,1.38,476.74k,0.70,7.73,,-19.12M,-2.78M,Value,M5X 1A4,Healthcare,9,"FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.",Toronto,416 854 8884,ON,1609372800,Canada,http://www.fsdpharma.com,86400,First Canadian Place,Drug Manufacturers—Specialty & Generic,Suite 3400 100 King Street West
t-2,HUGE,23430642.0,35991800,4668253,,-16486272,,-18034382,3734788,0,-16558387,-16558387,,-81054,,,,0,0,16558387,0,72115,-1548110,-16486272,-18034382,19131128.0,24279156.0,13641023.0,42561770.0,8977581.0,56202793.0,127085638.0,10963208.0,-114968252.0,6165228.0,18660730.0,13528428.0,6165228.0,35477989.0,1593676.0,4726545.0,3290037.0,-420636.0,188424.0,-800468.0,11920644.0,6156824.0,12721112.0,5272628.0,-6836440.0,1285169.0,-3172933.0,7349518.0,139751.0,48673.0,21949561.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,FSD Pharma Inc.,False,False,NCM,1.79,1630526403,-0.04000008,1.84,1.85,1.77,145980,PRE,0,4,-2.1857967,1.77 - 1.85,1.83,0.0,0.0,14,9,finmb_266208867,FSD Pharma Inc.,NasdaqCM,USD,346667,593357,0.51,0.3984375,1.28 - 4.44,-2.65,-0.5968469,1.28,4.44,1571184000,1615984200,1628166600,1628512200,1.6471429,0.14285707,0.08673023,1.8123913,-0.02239132,-0.012354572,64425320,15,America/New_York,EDT,-14400000,1.09,,,4.44,1.28,1.6471,1.8124,346.67k,593.36k,35.99M,,33.97M,12.91%,2.53%,945.83k,1.77,,2.63%,1.12M,,,,,,0.00%,"Oct 15, 2019",,1:201,"Oct 15, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-37.04%,-60.26%,,,,,-29.18M,-29.7M,,,49.84M,1.38,476.74k,0.70,7.73,,-19.12M,-2.78M,Value,M5X 1A4,Healthcare,9,"FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.",Toronto,416 854 8884,ON,1609372800,Canada,http://www.fsdpharma.com,86400,First Canadian Place,Drug Manufacturers—Specialty & Generic,Suite 3400 100 King Street West
t-3,HUGE,24959947.0,35991800,2075658,,-5218070,,-5971665,2537795,0,-6419139,-6419139,,-91019,,,,0,0,6419139,0,1201069,-753595,-5218070,-5971665,20860170.0,24078474.0,6200094.0,45820117.0,,52020211.0,112148128.0,11922750.0,-96933870.0,6527385.0,13388102.0,6075842.0,6527385.0,29354002.0,1806039.0,2070838.0,4192786.0,-102805.0,727032.0,-14051.0,9250262.0,609640.0,9264313.0,5029203.0,-4948091.0,1321730.0,-78254.0,-726737.0,727032.0,48673.0,23278160.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,FSD Pharma Inc.,False,False,NCM,1.79,1630526403,-0.04000008,1.84,1.85,1.77,145980,PRE,0,4,-2.1857967,1.77 - 1.85,1.83,0.0,0.0,14,9,finmb_266208867,FSD Pharma Inc.,NasdaqCM,USD,346667,593357,0.51,0.3984375,1.28 - 4.44,-2.65,-0.5968469,1.28,4.44,1571184000,1615984200,1628166600,1628512200,1.6471429,0.14285707,0.08673023,1.8123913,-0.02239132,-0.012354572,64425320,15,America/New_York,EDT,-14400000,1.09,,,4.44,1.28,1.6471,1.8124,346.67k,593.36k,35.99M,,33.97M,12.91%,2.53%,945.83k,1.77,,2.63%,1.12M,,,,,,0.00%,"Oct 15, 2019",,1:201,"Oct 15, 2019","Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-37.04%,-60.26%,,,,,-29.18M,-29.7M,,,49.84M,1.38,476.74k,0.70,7.73,,-19.12M,-2.78M,Value,M5X 1A4,Healthcare,9,"FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD 201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also develops drugs for the treatment of pain, inflammation, and neurological disorders. It has license agreements with Epitech Group SpA.; and with Innovet Italia S.R.L. to develop veterinary drugs for the treatment of gastro-intestinal diseases in dogs and cats. The company was founded in 1998 and is headquartered in Toronto, Canada.",Toronto,416 854 8884,ON,1609372800,Canada,http://www.fsdpharma.com,86400,First Canadian Place,Drug Manufacturers—Specialty & Generic,Suite 3400 100 King Street West
